北大医药(000788) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥362,812,695.12, a decrease of 25.50% compared to ¥487,014,401.13 in the same period last year[8] - The net profit attributable to shareholders for Q1 2020 was ¥10,257,967.08, down 32.19% from ¥15,128,451.92 in the previous year[8] - Basic earnings per share for Q1 2020 were ¥0.0172, a decrease of 32.28% from ¥0.0254 in the previous year[8] - Total operating revenue for Q1 2020 was CNY 362,812,695.12, a decrease from CNY 487,014,401.13 in the previous period[47] - Net profit for Q1 2020 was CNY 10,257,065.86, compared to CNY 15,126,964.87 in the same period last year, reflecting a decline of about 32%[49] - The net profit for the first quarter of 2020 was CNY 12,412,181.49, a decrease of 6.5% compared to CNY 13,272,973.66 in the same period last year[52] - The total profit amounted to CNY 14,885,216.23, down from CNY 15,962,971.18, reflecting a decline of approximately 6.7% year-over-year[52] - Operating income for the quarter was CNY 14,867,641.85, compared to CNY 15,938,908.67 in the previous year, indicating a decrease of about 6.7%[52] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥27,921,120.06, a decline of 124.64% compared to ¥113,334,438.60 in the same period last year[8] - Cash flow from operating activities showed a net outflow of CNY -27,921,120.06, contrasting with a net inflow of CNY 113,334,438.60 in the same quarter last year[54] - The company reported cash inflows from operating activities of CNY 447,205,856.53, compared to CNY 735,333,646.35 in the prior year, representing a decline of approximately 39.2%[54] - Total cash outflows from operating activities were CNY 475,126,976.59, a decrease from CNY 621,999,207.75 in the previous year[56] - The net cash flow from financing activities was CNY -17,888,894.41, compared to a net inflow of CNY 15,137,662.97 in the same quarter last year[57] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,350,760,044.87, down 4.23% from ¥2,454,711,880.11 at the end of the previous year[8] - The company's total liabilities decreased from CNY 1,208,374,644.92 at the end of 2019 to CNY 1,094,052,280.78, reflecting a reduction of about 9.45%[41] - Cash and cash equivalents decreased from CNY 668,912,856.83 at the end of 2019 to CNY 624,773,007.39, a decline of approximately 6.61%[39] - Total current assets amounted to CNY 2,200,729,015.18, with cash and cash equivalents at CNY 668,912,856.83[63] - Total liabilities reached CNY 1,208,374,644.92, with current liabilities accounting for CNY 1,193,141,674.44[64] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,395[11] - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., held 28.58% of the shares, amounting to 170,356,260 shares[11] - The company reported no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[29] Research and Development - R&D expenses rose by 118.87% to ¥1,842,713.96, reflecting increased investment in R&D activities[16] - The company is collaborating with SK Biopharmaceuticals and others on the development of the innovative drug SKL-PSL, with the project already receiving ethical review approval[17] - The company has committed to pay ¥27.5 million for the development of a new drug, with ¥5.5 million already paid for initial research[18][19] Operational Changes - The company signed a long-term service contract with Peking University International Hospital, with an estimated total contract value of ¥1 billion per year for three years[23] - The company is in the process of transferring 41% equity in a subsidiary, Beijing Peking University Medical Oncology Hospital Management Co., Ltd., through public listing[26] - The company is implementing new revenue and leasing standards starting from 2020, which may impact future financial reporting[67] Inventory and Receivables - Accounts receivable decreased by 82.85% to ¥5,375,076.60 due to bill discounting and transfer activities during the reporting period[16] - Inventory increased from CNY 160,173,564.26 at the end of 2019 to CNY 180,095,211.87, an increase of approximately 12.43%[39] Financial Management - The company has a financial services agreement with a maximum deposit balance of ¥500 million, with no loans applied as of March 31, 2020[20] - The company did not engage in any repurchase transactions during the reporting period[12] - There were no securities investments or entrusted financial management activities reported during the period[30][31] - The company did not engage in any derivative investments during the reporting period[32]